Sagent Pharmaceuticals Announces the Launch of Amikacin Sulfate Injection, USP
18 Julio 2016 - 7:00AM
Sagent Pharmaceuticals, Inc. (NASDAQ:SGNT) today announced the
launch of Amikacin Sulfate Injection, USP, an
anti-infective/antibiotic, in 500 mg per 2 mL and 1 g per 4
mL preservative-free vials. According to IMS, for the 12
months ending May 2016, the US market for Amikacin approximated $8
million. As with all products in Sagent's portfolio, Amikacin
features Sagent’s PreventIV MeasuresSM Packaging and Labeling,
designed to help reduce the risk of medication errors.
About Amikacin Sulfate Injection, USPAmikacin
Sulfate Injection, USP is indicated in the short-term treatment of
serious infections due to susceptible strains of Gram-negative
bacteria, including Pseudomonas species, Escherichia coli, species
of indole-positive and indole-negative Proteus, Providencia
species, Klebsiella-Enterobacter-Serratia species and Acinetobacter
(Mima-Herellea) species.
The package insert, available at www.SagentPharma.com, contains
the indications, boxed warnings, complete side effect profile and
prescribing information.
About Sagent Pharmaceuticals, Inc. Sagent
Pharmaceuticals, Inc., founded in 2006, is a leading provider of
affordable pharmaceuticals to the hospital market. Sagent has
created a unique, global network of resources, comprising rapid
development capabilities, sophisticated manufacturing and
innovative drug delivery technologies, resulting in an extensive
and rapidly expanding pharmaceutical product portfolio that
fulfills the evolving needs of patients.
INVESTOR CONTACT:
Jonathon Singer, Sagent
847-908-1605
jsinger@sagentpharma.com
Sagent (NASDAQ:SGNT)
Gráfica de Acción Histórica
De May 2024 a Jun 2024
Sagent (NASDAQ:SGNT)
Gráfica de Acción Histórica
De Jun 2023 a Jun 2024
Real-Time news about Sagent Pharmaceuticals, Inc. (NASDAQ): 0 recent articles
Más de Artículos de Noticias